Patent US5629008A successfully refreshed from Google Patents.
US5629008A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and device for long-term delivery of drugs
Assignee: CR Bard Inc
•
Filing: 1994-06-07
•
Granted: 1997-05-13
•
Expires: 2014-06-07
Abstract
Abstract The present invention is an implantable device that is capable of delivering a therapeutic agent to a tissue or organ over a long period of time. The implantable device is especially suited for treating tissues and organs that are comprised of smooth muscle. The implantable device can deliver either a single therapeutic agent or a plurality of therapeutic agents to the tissue or organ at zero order kinetics.
Inventors
- 👤 Clarence C. Lee
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 01:24
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/0034; A61M; A61M31/00; A61M31/002; A61K9/0087; A61K9/0092
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
90 words
An implant device for the long term delivery of a therapeutic agent to a tissue or organ, comprising: a container for implantation within the tissue or organ; and a therapeutic agent immobilized in a biodegradable matrix wherein said matrix is biodegradable by enzymatic or acid/base hydrolysis and contained within the container such that the therapeutic agent is released at a rate of at least approximately 0.1 μg/day over a period of at least approximately one month, said device having a diameter of between approximately 20 microns and approximately 3 cm.
Claim 2
Dependent Claim
90 words
An implant device for the long term delivery of a therapeutic agent to a tissue or organ, comprising: a container for implantation within the tissue or organ; and a therapeutic agent immobilized in a biodegradable matrix wherein said matrix is biodegradable by enzymatic or acid/base hydrolysis and contained within the container such that the therapeutic agent is released at a rate of at least approximately 0.1 μg/day over a period of at least approximately one month, said device having a diameter of between approximately 20 microns and approximately 3 cm.
Claim 3
Dependent Claim
19 words
The implant device of claim 1, wherein the container is comprised of a material which is impermeable to macromolecules.
Claim 4
Dependent Claim
29 words
The implant device of claim 2, wherein the rate of release of the therapeutic agent is controlled by a portion of the container being permeable to the therapeutic agent.
Claim 5
Dependent Claim
26 words
The implant device of claim 2, wherein the rate of release of the therapeutic agent is further controlled by controlling the permeability of the permeable portion.
Claim 6
Dependent Claim
26 words
The implant device of claim 2, wherein the rate of release of the therapeutic agent is further controlled by controlling the dimensions of the permeable portion.
Claim 7
Dependent Claim
23 words
The implant device of claim 1, wherein the rate of release is controlled by controlling the rate of biodegradation of the biodegradable matrix.
Claim 8
Dependent Claim
38 words
The implant device of claim 1, wherein the therapeutic agent is selected from the group consisting of antimuscarinic agents, anticholinergic agents, antispasmodic agents, calcium antagonist agents, potassium channel openers, musculotropic relaxants, polysynaptic inhibitors, beta-adrenergic stimulators and antitumor agents.
Claim 9
Dependent Claim
28 words
The implant device of claim 1, wherein the therapeutic agent is selected from the group consisting of propantheline bromide, imipramine, hyoscyamine sulfate, oxybutynin chloride, carmustine, dicyclomine and terodiline.
Claim 10
Dependent Claim
48 words
The implant device of claim 1, wherein the biodegradable matrix is selected from the group consisting of polylactide, polyanhydrides, polyglycolide, polylactide co-glycolide polypeptides, poly(ortho)esters, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, phospholipids, polysaccharides, polyamino acids, nucleic acids, phenylalanine, tyrosine, isoleucine, polynucleotides, polyethylene glycol, polyvinyl propylene, polyvinylpyrrolidone and beeswax.
Claim 11
Dependent Claim
12 words
The implant device of claim 1, wherein the container is a cylinder.
Claim 12
Dependent Claim
32 words
The implant device of claim 2, wherein the material which is impermeable to macromolecules is selected from the group consisting of stainless steel, gold, titanium, platinum, metal alloys, silicone, silastic and plastics.
Claim 13
Dependent Claim
25 words
The implant device of claim 11, wherein the plastic is selected from the group consisting of polyethylene, polypropylene, polycarbonate, polystyrene, polyethylene terephthalates, polyurethane and parylene.
Claim 14
Independent Claim
97 words
A method of treating a tissue or organ comprising the step of implanting an implant device into the tissue or organ, the implant device comprising: a container for implantation within the tissue or organ; and a therapeutic agent immobilized in a biodegradable matrix wherein said matrix is biodegradable by enzymatic or acid/base hydrolysis and contained within the container such that the therapeutic agent is released at a rate of at least approximately 0.1 μg/day over a period of at least approximately one month, said device having a diameter of between approximately 20 microns and approximately 3 cm.
Claim 15
Independent Claim
97 words
A method of treating a tissue or organ comprising the step of implanting an implant device into the tissue or organ, the implant device comprising: a container for implantation within the tissue or organ; and a therapeutic agent immobilized in a biodegradable matrix wherein said matrix is biodegradable by enzymatic or acid/base hydrolysis and contained within the container such that the therapeutic agent is released at a rate of at least approximately 0.1 μg/day over a period of at least approximately one month, said device having a diameter of between approximately 20 microns and approximately 3 cm.
Claim 16
Dependent Claim
18 words
The method of claim 13, wherein the container is comprised of a material which is impermeable to macromolecules.
Claim 17
Dependent Claim
28 words
The method of claim 13, wherein the rate of release of the therapeutic agent is controlled by a portion of the container being permeable to the therapeutic agent.
Claim 18
Dependent Claim
25 words
The method of claim 15, wherein the rate of release of the therapeutic agent is further controlled by controlling the permeability of the permeable portion.
Claim 19
Dependent Claim
24 words
The method of claim 15, wherein the rate of release of the therapeutic agent is controlled by controlling the dimensions of the permeable portion.
Claim 20
Dependent Claim
22 words
The method of claim 13, wherein the rate of release is controlled by controlling the rate of biodegradation of the biodegradable matrix.
Claim 21
Dependent Claim
37 words
The method of claim 13, wherein the therapeutic agent is selected from the group consisting of antimuscarinic agents, anticholinergic agents, antispasmodic agents, calcium antagonist agents, potassium channel openers, musculotropic relaxants, polysynaptic inhibitors, beta-adrenergic stimulators and antitumor agents.
Claim 22
Dependent Claim
21 words
The method of claim 19, wherein the therapeutic agent is propantheline bromide, imipramine, hyoscyamine sulfate, carmustine, oxybutynin chloride, dicyclomine and terodiline.
Claim 23
Dependent Claim
47 words
The method of claim 18, wherein the biodegradable matrix is selected from the group consisting of polylactide, polyanhydrides, polyglycolide, polylactide co-glycolide polypeptides, poly(ortho)esters, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, phospholipids, polysaccharides, polyamino acids, nucleic acids, phenylalanine, tyrosine, isoleucine, polynucleotides, polyethylene glycol, polyvinyl propylene, polyvinylpyrrolidone and beeswax.
Claim 24
Dependent Claim
11 words
The method of claim 13, wherein the container is a cylinder.
Claim 25
Dependent Claim
31 words
The method of claim 14, wherein the material which is impermeable to macromolecules is selected from the group consisting of stainless steel, gold, titanium, platinum, metal alloys, silicone, silastic and plastics.
Claim 26
Dependent Claim
25 words
The implant device of claim 23, wherein the plastic is selected from the group consisting of polyethylene, polypropylene, polycarbonate, polystyrene, polyethylene terephthalates, polyurethane and parylene.
References Cited (Backward Citations)
US3710795A
Cited
US4179846A
Cited
USRE32969E
Cited
US4725442A
Cited
US4595583A
Cited
EP0164241A2
Cited
US4627851A
Cited
US4693895A
Cited
US4723950A
Cited
US4775659A
Cited
US4822368A
Cited
US4803075A
Cited
US4913903A
Cited
US4871542A
Cited
US4792448A
Cited
US4828828A
Cited
US5059423A
Cited
EP0572932A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-12 | 2000-11-11 | 2001-05-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-12 | 2004-11-11 | 2005-05-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-12 | 2008-11-11 | 2009-05-13 | $7700.00 | Window Closed / Lapsed |